Eye Injections or Laser for Proliferative Diabetic Retinopathy: How to Choose
Choosing Between Injections and Laser at a Glance
Some changes in your sight need care right away. Call your eye doctor the same day. If you cannot reach the office, go to an emergency room. Watch for these changes in either eye:
- Sudden vision loss, or a fast drop in how well you see.
- A shower of new floaters, such as dark specks, dots, or cobwebs.
- New flashing lights.
- A dark curtain or shadow over part of your sight.
- New eye pain with a red eye.
These changes can mean bleeding inside the eye or a pulled retina, and both need prompt care1. Care that starts early gives your sight its best chance. Most people who call early are seen and treated in time. It is always better to call and be told all is well than to wait at home.
If you have proliferative diabetic retinopathy, you are choosing between two good options, not a right one and a wrong one. Scatter laser, known to doctors as panretinal photocoagulation or PRP, has protected sight for decades. Anti-VEGF injections are a newer option that works about as well on vision over five years. The American Academy of Ophthalmology treats both as accepted treatments, notes that many people end up receiving both, and says the best order to give them in has not been settled2.
The choice usually turns less on which treatment is stronger and more on your life: how easily you can get to appointments, whether you also have swelling at the center of the retina, and what your insurance covers. Your retina specialist will weigh these with you.
Retina specialists work through a short list of questions before recommending a path. They ask whether you already have swelling at the center of the retina, which injections treat at the same time, whether you can return every four to eight weeks in the first year, and whether pregnancy or transportation problems are in the picture.
The question about returning for visits matters more than it sounds, because in one study of eyes whose owners went more than six months without follow-up, sight at the return visit was worse in the injection-treated eyes than in the laser-treated eyes, and a pulling-type retinal detachment was found in 10 of 30 injection-treated eyes compared with 1 of 46 laser-treated eyes3. That is one small look-back study, not a rule about you, but it is why doctors ask about appointments first.
What Each Treatment Is and How It Works
Anti-VEGF injections are medicines placed into the jelly of the eye through a very fine needle, after numbing drops. VEGF is a growth signal that oxygen-starved retina releases, and it drives the fragile new vessels that define the proliferative stage. The medicine blocks that signal, so the vessels shrink back.
Aflibercept, sold as Eylea, carries diabetic retinopathy among its FDA-approved uses4, and ranibizumab, sold as Lucentis, was approved in 2017 for all forms of diabetic retinopathy5. A third drug, bevacizumab, sold as Avastin, is widely used in the eye off-label, meaning it is not FDA-approved for eye use but is used that way on published evidence and at much lower cost.
Scatter laser is done in the office with numbing drops and a contact lens on the eye. The doctor places hundreds of tiny laser spots across the outer retina, away from your reading vision. Those spots quiet the oxygen-starved tissue sending the growth signal, so the vessels regress and are much less likely to bleed. Heavier treatment is often split across more than one sitting, because treating a lot at once raises the chance of side effects6.
The trade is deliberate. Laser gives up a measure of side vision and night vision to protect the central sight you read with6. Most people find that trade worthwhile once it is explained.
Both treatments exist to stop one thing: fragile new vessels growing on the retina and into the jelly of the eye. Left alone, those vessels bleed and pull, which is how this disease takes sight. The original Diabetic Retinopathy Study of 1,758 patients showed that scatter laser lowered the rate of severe vision loss over two years from about 16 of every 100 untreated eyes to about 6 of every 100 treated eyes7. That result is why laser became the reference standard newer options are measured against.
These are not always rivals. Many people get an injection first to quiet active bleeding, then laser to lock in a longer-lasting effect. Others start with laser and add injections later if central swelling develops. Guideline authors note that combined use is common and that the best sequence has not been established by trials2. If your doctor proposes both, that is a recognized approach, not a sign the first treatment failed.
Injections and Laser Side by Side
On vision alone, the two are close over the long run. In the five-year DRCR Protocol S trial, average vision changed by about 3 letters on the eye chart in both groups, a difference too small to notice, and vision-impairing swelling at the center of the retina developed in about 22 of every 100 injection-treated eyes compared with about 38 of every 100 laser-treated eyes8.
| Measure | Anti-VEGF injections | Scatter laser |
|---|---|---|
| Average vision change at 5 years | About 3 letters gained | About 3 letters gained |
| Vision-impairing central swelling over 5 years | About 22 of every 100 eyes | About 38 of every 100 eyes |
| Vision at 1 year in a separate trial | About 4 letters better | Reference group |
The one-year figure comes from the CLARITY trial, where eyes treated with aflibercept read about 4 more letters than laser-treated eyes at 52 weeks with no safety concerns raised9. Four letters is less than one line on the chart, a real but modest edge.
This is where the two paths differ most, and it often decides the choice. Over five years in Protocol S, the injection group received roughly four times as many injections and made about three times as many visits as the laser group, and the injection path represented reasonable value for money only in eyes that also had vision-impairing central swelling10.
| What it asks of you | Anti-VEGF injections | Scatter laser |
|---|---|---|
| Typical treatment schedule | About 7 in the first year, fewer later | Often 1 to 3 sittings |
| Extra treatment often needed | Ongoing injections for years | Extra laser in about 51 of every 100 eyes |
| Visits over 5 years | About three times as many | Fewer |
Those treatment counts come from Protocol S, where injection-treated eyes averaged about 7 injections in year one and about 3 a year in years three through five, while about 51 of every 100 laser-treated eyes needed additional laser sessions11. Laser is not always one-and-done either, but its follow-up load is lighter.
Each treatment has its own side-effect pattern. Laser can cause swelling at the center of the retina, gaps in side vision, reduced night vision, and, less often, fluid collections under the retina, with risk tied to laser settings and heavy treatment in one sitting; newer pattern lasers reduce but do not remove these effects6.
| Side effect | More typical of |
|---|---|
| Reduced side vision and night vision | Scatter laser |
| Temporary blur and ache after treatment | Both, more so after laser |
| Serious infection inside the eye | Injections, and rare |
| Losing ground if appointments lapse | Injections |
In a national insurance-claims analysis of 818,558 injections, a serious infection inside the eye was recorded after 498 of them, roughly 6 of every 10,000 injections12. That risk is small but not zero, which is why new pain, redness, or a vision drop after an injection is worth a same-day call.
Which Treatment Tends to Fit Which Situation
Laser tends to be the more practical choice when steady attendance is uncertain. Laser keeps working after the course ends, and the evidence that it lowers severe vision loss over years is the oldest and most direct in this field7. Long travel and stretches when you cannot commit to monthly visits push toward laser.
Laser is also often favored when you have no central swelling to treat, since a main advantage of injections would not apply. That does not make laser second-best; it asks less of your calendar for a similar result.
Injections tend to be favored when you also have vision-impairing central swelling, because one treatment then addresses both problems. Pooled trial evidence in a Cochrane review of 23 randomised trials covering 1,755 people and 2,334 eyes found that anti-VEGF, with or without laser, probably improves vision by about 4 letters compared with laser alone, an amount the reviewers judged too small to be clinically meaningful, and probably reduces bleeding into the jelly of the eye13.
Injections also appeal when side vision matters a great deal, for example if you already have field loss from another condition. In the Protocol S field analysis, average side-vision loss over five years was greater in laser-treated eyes than in injection-treated eyes, though field data were available for only 79 of 234 eyes at that point, which makes the finding suggestive rather than settled11.
An injection plan only protects your eye while it continues. When injections stop, the growth signal returns and vessels can regrow, while laser leaves a lasting change in the retina. This is the practical reason the return-visit study found worse sight and more pulling-type retinal detachments in injection-treated eyes after a lapse of six months or more3.
This is not a reason for guilt or fear. It is a reason to be candid about your life. If you know a hard stretch is coming, say so, because a doctor who knows may add laser as a safety net.
Cost is a legitimate part of this decision. Injection medicines differ widely in price, and the off-label option is usually much cheaper. Over five years, the injection path in Protocol S represented reasonable value for money only in eyes that also had vision-impairing central swelling10.
Ask the office what your share of each option would be, including follow-ups. Many practices have staff who check coverage and find assistance programs, and that talk is easier before treatment than after.
Risks and the Realistic Outlook
Both paths landed in about the same place on vision. Five-year results from Protocol S showed no meaningful difference in average vision between the two groups, with the injection group having fewer new cases of vision-impairing central swelling8. These are group averages and cannot predict what your eye will do.
The Cochrane reviewers also found that anti-VEGF may reduce the need for surgery to clear the jelly of the eye, though they rated that evidence low-certainty and the safety comparison very low-certainty13. The vision case for injections is solid; the surgery case is promising but less firm.
Two limits deserve mention. In Protocol S, about a third of participants did not complete the five-year visit, which weakens how confidently the long-term comparison can be read8. That is common in long diabetes studies, and it is a reason to treat five-year figures as a guide rather than a guarantee.
The second limit is what neither treatment does. Neither restores sight already lost to bleeding or scarring, and neither treats the diabetes underneath. Both aim to hold the line so the vision you have now stays with you.
Sometimes neither is the next step. The National Eye Institute notes that surgery to remove the jelly of the eye is used when there is heavy bleeding inside the eye or a lot of scar tissue1. Needing it does not mean you or your doctor did anything wrong; it reflects how advanced the disease was when found.
This surgery is well established and often recovers useful vision. If it comes up, ask what the goal is and what result is realistic.
Follow-Up, Daily Care, and When to Call
After either treatment, most discomfort is mild and settles within a day or two. Contact your eye doctor the same day if you notice a sudden drop in vision, a new shower of floaters, a dark curtain in your sight, or an eye that turns painful and red. Those point to a fresh bleed, a detachment, or an infection, and each is treatable when caught early.
A red, painful eye after an injection is especially urgent, because that is the pattern an infection follows. Calling promptly is what your care team expects.
Your schedule depends on the path you take. Injection plans commonly begin with monthly visits and stretch out as the eye settles, while laser plans involve a few close visits and then routine checks. Protocol S gives a sense of the long-run difference: injection-treated eyes averaged about 3 injections a year even in years three to five11.
Whatever the plan, the visits are the treatment. Calendar reminders and rides arranged ahead of time matter more than any single decision made on day one.
Neither treatment removes the need to manage the diabetes behind the damage. The National Eye Institute states that managing diabetes is the best way to lower the risk of diabetic retinopathy and that people with diabetes need a dilated eye exam at least once a year1. Steady blood sugar and blood pressure give whichever treatment you choose a calmer eye to work on.
Progress here is cumulative, not perfect. Small, steady improvements ease the pressure on your eyes over years, and your eye and diabetes teams can work from one plan if you ask.
Proliferative diabetic retinopathy is managed by a retina specialist, an ophthalmologist with extra training in the back of the eye. Your optometrist or general ophthalmologist may find it and refer you onward, and both treatments are given by the specialist.
If you are at the proliferative stage and have no retina appointment yet, ask for one now rather than waiting for symptoms. This stage can be quiet at first, and getting into care early is the most protective step available.
Common Questions About Choosing Injections or Laser
Over five years the two came out about even on average vision in the largest head-to-head trial, with roughly a 3-letter gain in each group. Injections had an edge in avoiding central swelling and in preserving side vision. Laser needed far fewer visits. The better choice depends on your eye and your circumstances, not on one treatment being stronger.
Most people describe scatter laser as uncomfortable rather than painful. Numbing drops are used, and you sit at a machine with a contact lens on the eye. You will see bright flashes and may feel a pinprick or dull ache toward the end. Doctors can split treatment across sittings or add stronger numbing. Tell the team if it hurts, because there are options.
There is no fixed number, and your doctor will not know at the start. As a guide, in the five-year trial the injection group averaged about 7 in the first year, about 4 in the second, and about 3 a year after that. Some eyes need fewer, some more. Your schedule follows how your retina looks at each visit.
The medicine wears off, and the growth signal that drives the abnormal vessels comes back. In one look-back study of eyes that went more than six months without follow-up, injection-treated eyes had worse vision at the return visit and more pulling-type retinal detachments than laser-treated eyes. If you know a gap is coming, say so. Adding laser as a safety net is a common response.
Yes, and many people do. A common pattern is an injection to quiet things down, then laser for a longer-lasting effect. Another is laser first, with injections added later if central swelling appears. Guideline authors note that combined treatment is common and that the ideal sequence is unsettled. Being offered both is a recognized strategy, not a sign of failure.
Some blur is normal after both. After laser, blur from dilation and mild retinal swelling can last days to a few weeks and usually settles. After an injection, you may see floaters or haze for a day or two. Plan not to drive yourself home. Vision that drops sharply, or blur with pain and redness, deserves a same-day call.
More Questions People Ask About This Choice
Reduced night vision is a recognized effect of scatter laser, and some people notice more difficulty driving after dark. The degree varies with how much laser was needed and the settings used, and newer pattern lasers are gentler. Ask your doctor what to expect in your case, and have your night driving assessed afterward rather than assuming the worst.
Serious harm is uncommon. The main concern is infection inside the eye, which in a claims analysis of more than 800,000 injections was recorded after roughly 6 of every 10,000. Most people find the procedure brief and easier than expected. The safety rule is simple: new pain, growing redness, or a drop in vision after an injection means calling your eye doctor the same day.
It can, and it is worth raising early. Treatment choice and monitoring during pregnancy are decided jointly by your retina specialist and your obstetric team, because both your eye and the pregnancy are in the picture. This page cannot make that call for you. Tell both teams as soon as you know, and ask how often they want to check your eyes while you are pregnant.
No. This is a decision you can revisit, and many people do. Starting with injections does not rule out laser later, and having had laser does not close the door on injections if central swelling develops. Your retina looks different at each visit, and the plan is expected to change with it. Ask what your doctor is seeing and what would change the approach.
Bringing a short list makes the decision easier to share. Consider asking:
- Do I have swelling at the center of the retina as well, and does that point toward injections?
- How many visits would each option realistically ask of me in the first year?
- What would my out-of-pocket cost be for each option, including follow-up visits?
- How much side vision and night vision might laser cost me in my case?
- If I have trouble getting to appointments, what is your backup plan for my eye?
- What changes should make me call you the same day rather than wait for my next visit?
- National Eye Institute, National Institutes of Health (2024). Diabetic Retinopathy.
- American Academy of Ophthalmology, Preferred Practice Pattern (Retina/Vitreous Panel) (2024). Diabetic Retinopathy Preferred Practice Pattern.
- Ophthalmology (Obeid et al.), PubMed 30077614 (2019). Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
- U.S. Food and Drug Administration, Drugs@FDA label (2023). EYLEA (aflibercept) injection, FDA-approved prescribing information, BLA 125387.
- American Academy of Ophthalmology, clinical news headline (2017). FDA approves ranibizumab for all forms of diabetic retinopathy.
- Seminars in Ophthalmology, PubMed 29172937 (2018). Panretinal Photocoagulation: A Review of Complications.
- NIHR Health Technology Assessment, NCBI Bookshelf NBK305100 (2015). The landmark trials: Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study (in: Pan-retinal photocoagulation and other forms of laser treatment for diabetic retinopathy, NIHR HTA systematic review).
- JAMA Ophthalmology (DRCR Retina Network), PubMed 30043039 (2018). Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial (DRCR Protocol S).
- The Lancet, PubMed 28494920 (2017). Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
- JAMA Ophthalmology (Hutton et al., DRCR Protocol S secondary analysis) (2019). Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
- Ophthalmology Retina / DRCR Retina Network, PMC7042909 (2020). Visual Field Outcomes at 5 Years in Eyes Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy (Protocol S post hoc analysis).
- BMJ Open Ophthalmology, PMC6124467 (2018). Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis.
- Cochrane Database of Systematic Reviews, PMC10026605 (2023). Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Cochrane Database of Systematic Reviews, CD008721.pub3).